Stem Cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 12, 2004, Pages 2333-2338

  Febbraio, Maria ^a   Guy, Ella ^b   Silverstein, Roy L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apo E null mice; CD36 atherosclerosis; Macrophages; Scavenger receptor

Indexed keywords

CD36 ANTIGEN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IRRADIATION; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE CD36; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIGENS, CD36; ARTERIOSCLEROSIS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; STEM CELL TRANSPLANTATION;

EID: 10644255811     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000148007.06370.68     Document Type: Article

References (32)

1. Loewen CJ, Levine TP. Cholesterol homeostasis: not until the SCAP lady INSIGs. Curr Biol. 2002;12:R779-R781.
2. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002;110:905-911.
3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
4. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
5. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982-49988.
6. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268:11811-11816.
7. Nicholson AC, Pearce SFA, Silverstein RL. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol. 1995;15:269-275.
8. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095-1108.
9. Han J, Hajjar DP, Febbraio M, Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 1997;272:21654-21659.
10. Han J, Hajjar DP, Tauras JM, Nicholson AC. Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J Lipid Res. 1999;40:830-838.
11. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 1996;87:2020-2028.
12. Yesner LM, Huh HY, Pearce SF, Silverstein RL. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol. 1996;16:1019-1025.
13. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM, Jr., Nicholson AC. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J Biol Chem. 2000;275:1241-1246.
14. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998;93:229-240.
15. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
16. Nakagawa-Toyama Y, Yamashita S, Miyagawa J, Nishida M, Nozaki S, Nagaretani H, Sakai N, Hiraoka H, Yamamori K, Yamane T, Hirano K, Matsuzawa Y. Localization of CD36 and scavenger receptor class A in human coronary arteries-a possible difference in the contribution of both receptors to plaque formation. Atherosclerosis. 2001;156:297-305.
17. Gelhaus A, Scheding A, Browne E, Burchard GD, Horstmann RD. Variability of the CD36 gene in West Africa. Hum Mutat. 2001;18:444-450.
18. Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, Yoshida S, Takahashi Y, Fuda H, Hui SP, Akita H, Kobayashi K, Matsuno K. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost. 2000;84:436-441.
19. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, Kameda-Takemura K, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest. 1995; 96:1859-1865.
20. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-791.
21. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716-719.
22. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657-1666.
23. Ryeom SW, Silverstein RL, Scotto A, Sparrow JR. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J Biol Chem. 1996;271:20536-20539.
24. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277:38503-38516.
25. Podrez EA, Hoppe G, O'Neil J, Hoff HF. Phospholipids in oxidized LDL not adducted to apoB are recognized by the CD36 scavenger receptor. Free Radic Biol Med. 2003;34:356-364.
26. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
27. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
28. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, Meade D, Li XA, Zhu W, Uittenbogaard A, Wilson ME, Smart EJ. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389-397.
29. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003;92:34J-41J.
30. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol. 2003;85:267-273.
31. Nencioni A, Wesselborg S, Brossart P. Role of peroxisome proliferator-activated receptor γ and its ligands in the control of immune responses. Crit Rev Immunol. 2003;23:1-13.
32. Tham DM, Wang YX, Rutledge JC. Modulation of vascular inflammation by PPARs. Drug News Perspect. 2003;16:109-116.